LEXICON PHARMACEUTICALS, INC. Debt Instrument, Fair Value Disclosure
LEXICON PHARMACEUTICALS, INC. (LXRX) had Debt Instrument, Fair Value Disclosure of $11.90 million as of 2021-09-30, per its 10-Q filed 2021-11-09.
Discontinued › Notes › Debt › Debt Instruments
us-gaap:DebtInstrumentFairValue · last filed 2021-11-09
- 2021-09-30: Debt Instrument, Fair Value Disclosure $11.90M.
- 2021-06-30: Debt Instrument, Fair Value Disclosure $12.10M.
- 2021-03-31: Debt Instrument, Fair Value Disclosure $12.60M.
- 2020-12-31: Debt Instrument, Fair Value Disclosure $9.20M.
| Period end | Debt Instrument, Fair Value Disclosure |
|---|---|
| 2021-09-30 | $11.90M 10-Q · filed 2021-11-09 |
| 2021-06-30 | $12.10M 10-Q · filed 2021-08-06 |
| 2021-03-31 | $12.60M 10-Q · filed 2021-05-06 |
| 2020-12-31 | $9.20M 10-K · filed 2021-03-12 |
| 2020-09-30 | $15.40M 10-Q · filed 2020-10-30 |
| 2020-06-30 | $44.70M 10-Q · filed 2020-07-29 |
| 2020-03-31 | $55.20M 10-Q · filed 2020-04-27 |
| 2019-12-31 | $64.80M 10-K · filed 2020-03-12 |
| 2019-09-30 | $76.00M 10-Q · filed 2019-11-07 |
| 2019-06-30 | $95.60M 10-Q · filed 2019-08-01 |
| 2019-03-31 | $90.70M 10-Q · filed 2019-05-01 |
| 2018-12-31 | $97.50M 10-K · filed 2019-03-15 |
| 2018-09-30 | $130.90M 10-Q · filed 2018-11-01 |
| 2018-06-30 | $145.90M 10-Q · filed 2018-07-30 |
| 2018-03-31 | $111.90M 10-Q · filed 2018-05-03 |
| 2017-12-31 | $127.30M 10-K · filed 2018-03-01 |
| 2017-09-30 | $141.60M 10-Q · filed 2017-11-08 |
| 2017-06-30 | $165.50M 10-Q · filed 2017-08-01 |
| 2017-03-31 | $161.10M 10-Q · filed 2017-05-04 |
| 2016-12-31 | $160.50M 10-K · filed 2017-03-06 |
| 2016-09-30 | $197.70M 10-Q · filed 2016-11-07 |
| 2016-06-30 | $159.80M 10-Q · filed 2016-08-04 |
| 2016-03-31 | $144.70M 10-Q · filed 2016-05-05 |
| 2015-12-31 | $154.20M 10-K · filed 2016-03-11 |
| 2015-09-30 | $129.80M 10-Q · filed 2015-11-09 |
| 2015-06-30 | $100.70M 10-Q · filed 2015-08-07 |
| 2015-03-31 | $87.50M 10-Q · filed 2015-05-05 |
| 2014-12-31 | $81.00M 10-K · filed 2015-03-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| GYRE THERAPEUTICS, INC. (GYRE) | United States | $0.818B | -24.71 |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| Avalo Therapeutics, Inc. (AVTX) | United States | $0.842B | -9.74 |
| GERON CORP (GERN) | United States | $0.803B | -12.14 |
| Aclaris Therapeutics, Inc. (ACRS) | United States | $0.792B | -9.78 |
| Olema Pharmaceuticals, Inc. (OLMA) | United States | $0.790B | -5.35 |
| ARDELYX, INC. (ARDX) | United States | $0.857B | -22.86 |
| Wave Life Sciences, Inc. (WVE) | $0.780B | -5.56 | |
| Design Therapeutics, Inc. (DSGN) | United States | $0.766B | -12.78 |